此应用程序的某些内容目前无法使用。
如果这种情况持续存在,请联系我们反馈与联系
1. (WO2019064071) CRYSTALLINE FORMS OF DIAZABICYCLOOCTANE DERIVATIVES AND PRODUCTION PROCESS THEREOF
注:相关文本通过自动光符识别流程生成。凡涉及法律问题,请以 PDF 版本为准

CLAIMS

1. A crystalline form V of a compound represented by Compound (I):


Compound (I)

having an X-ray powder diffraction pattern with characteristic peaks expressed in values of degrees 2Θ at about 17.1, about 18.8, and about 20.2 ±0.2.

2. The crystalline form V according to claim 1, wherein the X-ray powder diffraction pattern has characteristic peaks expressed in values of degrees 2Θ at about 15.7 and about 23.1

±0.2.

3. The crystalline form V according to claim 1, wherein the X-ray powder diffraction pattern has characteristic peaks expressed in values of degrees 2Θ at about 15.7; about 17.1; about 18.8; about 20.2; and about 23.1 ±0.2.

4. The crystalline form V according to claim 1, wherein the X-ray powder diffraction pattern has characteristic peaks expressed in values of degrees 2Θ at about 7.4; about 12.2; about 15.7; about 17.1; about 18.5; about 18.8; about 20.2; about 20.4; about 21.8; about 22.5; about 23.1; about 24.3; about 25.1; about 25.4; about 26.5; about 28.0; about 29.7; about 30.5; about 30.7; about 31.4; and about 34.1 ±0.2.

5. A process for producing a crystalline form V of a compound represented by Compound (I):

Compound (I)

comprising:

(a) dissolving Compound (I) in a solvent, to form a solution of Compound (I);

(b) agitating the solution of Compound (I);

(c) filtering by centrifugation of the solution of Compound (I); and,

(d) evaporating the solution, to produce crystalline form V of Compound (I).

6. The process according to claim 5, wherein the solvent is water, ethanol, or a mixture

thereof.

7. The process according to claim 5, wherein the agitation of the solution occurs for at least 22 hours.

8. The process according to claim 5 further comprising drying the crystalline form V of

Compound (I) at 22 ±1°C under a reduced pressure of no more than 5 mbar for at least 20 hours.

9. A method for treating a bacterial infection in a subject in need thereof comprising

administering to the subject a therapeutically effective amount of crystalline form V of Compound (I) according to claim 1.

10. A pharmaceutical composition comprising crystalline form V of Compound (I) according to claim 1 and a pharmaceutically acceptable carrier, pharmaceutical excipient, or a pharmaceutical diluent.

11. A method for treating a bacterial infection in a subject in need thereof comprising administering to the subject a therapeutically effective amount of the pharmaceutical composition according to claim 10.

12. A method for treating a bacterial infection in a subject in need thereof comprising

administering to the subject a pharmaceutical composition according to claim 10 in amount sufficient to inhibit a bacterial beta-lactamase.

13. A method for treating a bacterial infection in a subject in need thereof comprising

administering to the subject a therapeutically effective amount of a crystalline form V of Compound (I) according to claim 1 and a therapeutically effective amount of a β-lactam antibiotic.

14. The method according to claim 13, wherein the β-lactam antibiotic is a penicillin, a

cephalosporin, or a monobactam.

15. A crystalline form VI of a compound represented by Compound (I):


Compound (I)

having an X-ray powder diffraction pattern with characteristic peaks expressed in values of degrees 2Θ at about 16.7; about 22.4; and about 23.7 ±0.2.

16. The crystalline form VI according to claim 15 having characteristic peaks expressed in values of degrees 2Θ at about 14.3 and about 17.2 ±0.2.

17. The crystalline form VI according to claim 15, having characteristic peaks expressed in values of degrees 2Θ at about 14.3; about 16.7; about 17.2; about 22.4; and about 23.7 ±0.2.

18. The crystalline form VI according to claim 15, having characteristic peaks expressed in values of degrees 2Θ at about 7.9; about 11.0; about 11.7; about 13.5; about 14.3; about 16.7; about 17.2; about 18.9; about 20.1; about 21.4; about 22.0; about 22.4; about 22.7; about 23.5; about 23.7; about 24.5; about 25.0; about 27.1; about 27.4; about 28.0; about 31.2; about 31.8; and about 35.6 ±0.2.